Navigation Links
Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Date:11/6/2007

In Phase I Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa;

Matched Antidote Rapidly Reverses Anticoagulant Effect

ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today presented encouraging data from Phase Ia and Phase Ib dose escalation studies of the Company's REG1 Anticoagulation System. REG1 is a two-component system consisting of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The data showed RB006 completely inhibited the activity of Factor IXa, a protein essential to blood clotting, and RB006's activity was rapidly and safely reversed by RB007 in the Phase I studies. Confirming previously reported Phase I results, these data were presented at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

"These Phase I results are encouraging, and this system should be evaluated further in confirmatory Phase II and III clinical studies. Experienced clinicians recognize the importance of being able to titrate the intensity of anticoagulation according to specific patient needs. Current drugs do not offer an optimal level of control or flexibility," said Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "Should additional well-controlled clinical studies confirm these data, REG1 may have potential for broad applications in clinical practice settings from the emergency room to the operating room."

Scientists from the Duke Clinical Research Institute and Regado analyzed REG1 pharmacokinetics and dosing data from 134 subjects enrolled in two of the three Phase I studies. The Phase Ia study enrolled 84 healthy volunteers; the Phase Ib study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results of the analysis showed an int
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015 Soligenix, Inc. (OTCQB: SNGX) ... committed to developing products that address unmet medical needs ... today that its President and Chief Executive Officer, ... presentation at the 27 th Annual ROTH Conference ... Tuesday, March 10, 2015 at 1:00 PM Pacific Daylight ...
(Date:3/5/2015)... , March 5, 2015 ... new generation of OASIS *    at ECR ... processing power will set a benchmark for patient-centric care. ... and prevent delays whilst optimizing workflow management and costs. ... comfort and safety for imaging in Neurology, Orthopaedics, Paediatrics, ...
(Date:3/5/2015)... Denmark , March 5, 2015 ... that applies its innovative TransCon technology to address ... present two posters at the ENDO 2015 conference ... The posters will be presented on Thursday, March ... is being held from 1:00pm-3:00pm PST, and are ...
Breaking Medicine Technology:Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3Ascendis Pharma to Present at ENDO 2015 2
... for Regulatory Effectiveness reports that the President,s Budget ... for beneficiaries who use home oxygen and other ... the ability of Medicaid beneficiaries to remain in ... home medical care as a cost-saving alternative to ...
... BOSTON, Feb. 14, 2012   Solos Endoscopy, Inc. (OTCPK: ... has completed the retirement of one hundred fifty million ... in exchange for Series B Convertible Preferred Shares. The ... now been cancelled and returned back to the Company ...
Cached Medicine Technology:President's Budget Declares War on Medicaid Recipients 2Solos Endoscopy, Inc. Announces Retirement of 150 Million Common Shares 2
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is expected ... 2014 to 2019. , The global digital PCR (dPCR) and qPCR ... 2014 to 2019. Although the mature markets such as the U.S., ... (dPCR) and qPCR market the Asia-Pacific region is expected to grow ... growth of the digital PCR (dPCR) and qPCR market is driven ...
(Date:3/5/2015)... 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread concern ... eco-friendly building materials made primarily from bamboo, stands ... all their flooring products for volatile organic compounds ... Benchmark International (BMH). Results from formaldehyde emissions ...
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a leading ... market, reported record revenue of $4.79 million for the ... million in the year-ago fourth quarter demonstrating the Company’s ... strong fourth quarter revenue growth reflects the market’s growing ... driving increased surgeon adoption of our unique product portfolio ...
(Date:3/5/2015)... Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) filed ... strokes and other serious cardiovascular events due to their ... forward in the federal multidistrict litigation now underway in ... a Case Management Order issued on March 3rd, the ... master pleadings in the proceeding. Among other things, the ...
(Date:3/5/2015)... Rhode Island Medical Imaging (RIMI) was pleased to donate ... the Providence College (PC) women’s basketball program’s fight to end ... ‘Think Pink’ uniforms, which were worn during the February 22nd ... at Alumni Hall/Mullaney Gymnasium in Providence, R.I. , ... women’s basketball’s ‘Pink Out’ event,” said Dr. Scott Levine of ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... Feb. 25 MedCath Corporation,(Nasdaq: MDTH ) announced ... Raymond James 29th Annual Institutional Investors,Conference held March 2-5 ... MedCath,s senior management will give its presentation on Monday, ... web cast live over the Internet,via MedCath,s website ...
... donors to become the first in the country to benefit ... ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a leader in finger-based ... Blood Center is deploying BIO-key,s WEB-key(R) biometric,identification technology to enhance ...
... Could Save Millions Their Sight, PORTLAND, Ore., ... has only approved Avastin for cancer of the ... proving itself as a "miracle,drug" that,s currently used ... prostate, renal cell, head and neck, pancreatic, ovarian,and ...
... BOSTON, Feb. 25 Cell phones have become ... immediate and often,location independent. Connecting can be intimate ... more visually engaging with new MMS,(Multimedia Messaging Service) ... inspire, motivate or simply make someone smile., ...
... the first module, targeting ... ... the,Healthcare Information and Management Systems Society (HIMSS) 2008 Annual,Conference & Exhibition, ... a software-based solution designed to,help healthcare organizations identify potential adverse events ...
... Hospice Now Serves as HIV/AIDS Care Hub, LOS ... filing of a lawsuit against the City of Los ... of contract and for a,"judicial determination" regarding the validity ... US, largest non-profit HIV/AIDS,healthcare, research, prevention and education provider. ...
Cached Medicine News:Health News:Indiana Blood Center Signs BIO-key(R) Contract 2Health News:Indiana Blood Center Signs BIO-key(R) Contract 3Health News:Off-Label Avastin Use for Wet Macular Degeneration 2Health News:Off-Label Avastin Use for Wet Macular Degeneration 3Health News:Family, Friends and Support Groups Add Picture Messaging to Inspire and Motivate - Anywhere, Anytime 2Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 2Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 3Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 4Health News:AHF Sues L.A. Housing Dept. to Prevent Closure of AIDS Site 2Health News:AHF Sues L.A. Housing Dept. to Prevent Closure of AIDS Site 3Health News:AHF Sues L.A. Housing Dept. to Prevent Closure of AIDS Site 4Health News:AHF Sues L.A. Housing Dept. to Prevent Closure of AIDS Site 5
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
... The assay is an immunometric ... of LH in human serum or ... bound by 2 monoclonal anti-LH antibodies ... is attached to magnetic particles and ...
... (LH) is a glycoprotein secreted by the ... and TSH, the intact LH molecule is ... These glycoproteins all have homologous alpha-subunits, however ... LH and FSH production and secretion are ...
Medicine Products: